Nasal spray aims to tame brain inflammation in ALS
NCT ID NCT07688239
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study tests whether a nasal spray called foralumab is safe and tolerable for people with ALS, a disease that damages nerve cells controlling movement. Foralumab is designed to calm inflammation and immune activity thought to contribute to ALS. About 44 adults aged 18 to 75 will receive either foralumab or a placebo for 12 weeks, then all will receive foralumab for another 12 weeks. Researchers will monitor safety, blood and spinal fluid markers, and brain inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- foralumab (nasal spray)
- What this could lead to
- If successful, this could point toward a new way to slow ALS progression by calming brain inflammation.
- What could go wrong
- This is an early-phase trial with only 44 participants, so results may not apply broadly. The treatment may not show benefit or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain implant aims to give voice to those trapped in silence
- Robotic arm could help people with paralysis regain independence at home
- Scientists hunt for biological clues to how ALS drug affects the body
- Could your own stem cells heal your brain? new trial tests it
- Experimental cell therapy tested in 3 ALS patients
- Gene therapy injection hopes to slow ALS